International Hippocrates Congress On Medical And Health Sciences, Ankara, Turkey, 1 - 03 March 2019, pp.763
The purpose of this study was to determine the pharmacokinetic interaction between ivermectin (0.4 mg/kg) and praziquantel (10 mg/kg) administered either alone or co-administered to dogs after oral treatment. Twelve healthy cross-bred dogs (weighing 18–21 kg, aged 1–3 years) were allocated randomly into two groups of six dogs (four females, two males) each. In the first group, the tablet formulation of praziquantel and ivermectin were administered using a crossover design with a 15-day washout period, respectively. The second group received tablet formulation of ivermectin plus praziquantel. Plasma concentrations of ivermectin and praziquantel were determined by high performance liquid chromatography using a fluorescence and ultraviolet detector respectively, and analyzed using non-compartmental methods. The pharmacokinetic parameters of ivermectin following oral alone-administration were as follows: elimination half-life (t1/2λz) 110 ± 11.06 h, area under the plasma concentration-time curve (AUC0–∞) 7805 ± 1768 h.ng/mL, maximum concentration (Cmax) 137 ± 48.09 ng/mL, and time to reach Cmax (tmax) 14.0 ± 4.90 h. The pharmacokinetic parameters of praziquantel following oral alone-administration were as follows: t1/2λz 7.39 ± 3.86 h, AUC0–∞ 4301 ± 1253 h.ng/mL, Cmax 897 ± 245 ng/mL, and tmax 5.33 ± 0.82 h. Pharmacokinetics of ivermectin and praziquantel were not changed, except tmax of praziquantel in the combined group. In conclusion, the combined formulation of ivermectin and praziquantel can be preferred in the treatment and prevention of diseases caused by susceptible parasites in dogs.